Electric fields + chemo + radiation: a new attack on brain cancer?
NCT ID NCT04474353
First seen Jan 02, 2026 · Last updated Jun 19, 2026 · Updated 33 times
Summary
This early-phase study tested a combination of tumor treating fields (a device that creates electric fields to disrupt cancer growth), stereotactic radiosurgery (precise radiation), and temozolomide chemotherapy in 12 adults with newly diagnosed glioblastoma. The main goal was to see if the combination is safe and to identify any severe side effects. The study is complete, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94304, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tumor treating fields (TTFields) device, temozolomide chemotherapy, and stereotactic radiosurgery
What this could lead to
If successful, this combination could offer a new way to control glioblastoma, potentially extending survival with manageable side effects.
What could go wrong
This is a very early phase 1 trial with only 12 people, so it's mainly checking safety, not effectiveness. The treatment may not work better than standard care and could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.